Patient access analytics and services software for rare disease brands
Claritas Rx builds patient-journey analytics and intervention software for specialty and rare disease pharma brands, running a TypeScript/NestJS and React stack on AWS ECS, Aurora and DynamoDB. The density of AWS security tooling (GuardDuty, Security Hub, CloudTrail, KMS, WAF, Config) plus a Compliance Director search and SOC 2 work points to a regulated-data business hardening its security posture as engineering-heavy hiring accelerates.
Notable leadership hires: Compliance Director
Claritas Rx, founded in 2011 and headquartered in South San Francisco, California, provides software and data services that help rare disease and specialty therapy brands keep patients on treatment. Its products combine real-world data, analytics, AI and embedded CRM functionality to anticipate access problems, lift therapy starts and refills, and cut abandonment. The company is privately held with 51–200 employees and hires in the United States. Its platform includes a patient intervention and patient services support suite along with channel management tooling.
Claritas Rx runs on AWS (ECS, Aurora, DynamoDB, CloudWatch) with Terraform and AWS CDK, a TypeScript/NestJS backend with PostgreSQL and TypeORM, and a React frontend using Vite, Tailwind CSS and Radix UI.
Yes. Engineering dominates Claritas Rx's open roles, skewed toward senior levels, with hiring accelerating in the United States alongside ops, legal and finance positions including a Compliance Director.
Claritas Rx is headquartered in South San Francisco, California. The privately held company was founded in 2011 and has 51–200 employees.
Other companies in the same industry, closest in size
Claritas Rx's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.